In this study : 30 patients with metastatic prostate cancer who admitted to the department of Oncology, Tishreen University Hospital, Lattakia, Syria between 2013 and 2014 were grouped according to gleason score , age and body mass index. All patient received treatment with LHRH agonist (goserelin 3,6 mg subcutaneous injection monthly) combined with anti-androgen for two weeks. PSA and testosterone were measured in all patients before treatment then after 1 and after 6 month and the side effects were documented. Results post ADH treatment: There is no relationship between body mass index and testosterone level. Hormonal treatment with LHRH agonist reduced testosterone to 50 ng/dl in 09% of the patients, whereas 76%of the cases achieved testosterone levels 20ng/dl. The most common treatment-related adverse event was depression 72% , hot flash %33 and headache 30%.